Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses updated treatment guidelines for alopecia areata in Japan, highlighting new options like corticosteroid pulse therapy, but reports no new clinical results.

This study found no differences in trace element concentrations between Finnish alopecia patients and the normal population, but noted significant serum copper variation among different alopecia subtypes.

This study reported successful treatment of biotin deficiency in three patients receiving total parenteral nutrition, suggesting current biotin supplementation recommendations may be inadequate to maintain normal biotin status.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.

This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.

This study found that the yellow dot pattern observed in dermoscopy of alopecia areata corresponds to inefficient follicular structures containing hair remnants, as corroborated by reflectance confocal microscopy and pathological findings.

This study discovered a novel interaction between the vitamin D receptor and LEF1, essential for normal Wnt signaling in keratinocytes, which is crucial for regular hair cycling.

This study observed a strong negative association between the HLA-DQB1*0201 allele and the alopecia totalis/alopecia universalis phenotype in Caucasian individuals, indicating a potential protective role.

This abstract reviews the causes and prognosis of alopecia areata but reports no new clinical findings.

This study reports that topical ruxolitinib failed to induce hair growth in a 66-year-old patient with alopecia areata, highlighting the need to explore factors affecting treatment response and compare topical vs oral administration outcomes.

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

This article discusses hair loss in postmenopausal women as often being multifactorial, reviewing various conditions affecting this group, but reports no new research findings.

Minoxidil can cause allergic reactions like burning, itching, and red bumps.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This study reports two cases of hair loss outcomes in patients using dupilumab for atopic dermatitis, with one showing improvement in alopecia universalis and another experiencing worsening of alopecia totalis.

This study found that a combination therapy of oral corticosteroid and oral PUVA led to scalp hair regrowth in patients with intractable alopecia totalis and universalis within two months.

This study investigated alkaline phosphatase activity in scalp biopsies from patients with alopecia areata and totalis, but provides no new conclusive clinical results.

The document concludes that correct diagnosis of alopecia types is crucial, scalp biopsies are important, and more research is needed.

This study reviewed existing articles to assess the efficacy of topical diphenylcyclopropenone immunotherapy for alopecia areata, but it did not report new clinical results.

In this updated guideline, the British Association of Dermatologists' expert group provided 49 management recommendations for alopecia areata and highlighted future research priorities, aiming to improve care for individuals affected by this condition.

This piece explains that 90% to 95% of pediatric alopecia cases are due to four main causes: alopecia areata, telogen effluvium, tinea capitis, and trichotillomania, with diagnosis typically confirmed through careful examination.

This study found that patients with alopecia areata had an increased risk of mortality from self-harm, psychiatric diseases, and lung cancer compared to the general population.

In this study, oral steroid pulse therapy was found to be as effective and well-tolerated as intravenous pulse therapy in treating severe alopecia areata, especially when started within one year of disease onset.

This study found that patients with alopecia areata have lower levels of RBC folate, correlating negatively with the disease's severity and extent.

In this study, a marine protein-based agent improved hair growth in subjects with various types of hair loss over a 12-month period, with good tolerability and no reported side effects.

This study found that a series of three monthly courses of medium-dose prednisolone pulse therapy was effective and well tolerated in most patients with active, multifocal alopecia areata but not in those with totalis/universalis.

This Italian study observed that one third of patients with 25 to 50% scalp hair loss from alopecia areata still experienced active patchy disease at long-term follow-up, and another third progressed to more severe forms like alopecia totalis or universalis, with limited recovery.

This study found that 1% minoxidil topical solution led to terminal hair regrowth in 25 out of 48 patients with alopecia areata, but only 11 patients achieved cosmetically acceptable results.

This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.